Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Deferred Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Current Deferred Revenue for 12 consecutive years, with $399000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 34.7% to $399000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $399000.0, a 34.7% decrease, with the full-year FY2025 number at $399000.0, down 34.7% from a year prior.
  • Current Deferred Revenue was $399000.0 for Q4 2025 at Niagen Bioscience, up from $292000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $611000.0 in Q4 2024 to a low of $141000.0 in Q1 2022.
  • A 5-year average of $223789.5 and a median of $184000.0 in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 42.09% in 2021, then soared 213.33% in 2024.
  • Niagen Bioscience's Current Deferred Revenue stood at $161000.0 in 2021, then fell by 2.48% to $157000.0 in 2022, then rose by 24.2% to $195000.0 in 2023, then skyrocketed by 213.33% to $611000.0 in 2024, then plummeted by 34.7% to $399000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Current Deferred Revenue are $399000.0 (Q4 2025), $292000.0 (Q3 2025), and $303000.0 (Q2 2025).